Antidiabetics Market Size & Share 2020 to 2026
Market Size by Product (Insulin {Rapid Acting, Long Acting, Premixed Insulin, Short Acting, Intermediate Acting}, Drug Class {Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, GLP-1 Agonist, Meglitinides, DPP-4 Inhibitors, SGLT-2, Thiazolidinedione}), by Patient Population (Pediatric, Adult, Geriatric), by Route of Administration (Insulin Syringe/Insulin Pen, Insulin Pump, Intravenous Infusion, Oral), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, & Forecast.
Report ID: GMI504
|
Published Date: June 2020
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
Antidiabetics Market Size
Antidiabetics Market size was USD 65.5 billion in 2019 and will grow at a CAGR of 10.7% from 2020 to 2026.
Increasing prevalence of diabetes across the globe will stimulate the market potential for antidiabetics drugs during forecast period. Need for effective treatment with low side effects will result into increasing R&D spending by pharmaceutical firms for drug development. Thus, escalating demand and adoption of antidiabetic drugs in developing as well as developed nations will boost the market growth in the upcoming period.
Antidiabetics Market Analysis
According to the European Society of Cardiology, diabetic population is estimated to reach at 628.6 million by 2045. Management of diabetes requires timely intervention and medication throughout the patients lifetime due to lack of curative drugs. Advancement in antidiabetic drugs has resulted into increased success rates and minimized complications.
For instance, various new drugs including dipeptidyl peptidase-4 inhibitors, selective sodium glucose cotransporter 2 inhibitors and unique peroxisome proliferator-activated receptor agonists are in development stages. Introduction of new mechanisms have increased opportunities for combination therapies. Hence, public and organizational efforts to innovate in diabetes drugs space will impel the market size in near future.
However, considerable cost of insulin may limit antidiabetics market growth upto some extent in developing countries.
Insulin segment is further segmented as rapid acting analog, long acting analog, premixed insulin, short acting analog, intermediate acting insulin. Drug class is sub classified into alpha glucosidase inhibitors, biguanides, sulphonylureas, GLP-1 (Glucagon like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) inhibitors and thiazolidinedione.
Insulin market constituted significant market share in 2019 and is expected to proceed at lucrative 12.4% CAGR. Introduction of short-acting analog has enhanced its post-prandial glucose-controlling ability in both type 1 and type 2 diabetic patients. Furthermore, with increase in type-2 diabetic patient pool, the segment will witness unprecedented growth during analysis period.
Geriatric population segment held over USD 27 million revenue in 2019. According to the European Society of Cardiology, among the total disease burden approximately 39.7% was due to population growth and ageing. Upsurge in geriatric population has contributed to significant diabetes burden.
With advancing age, prevalence of type 2 diabetes increases along with escalated risk of coronary heart diseases, vascular diseases and stroke. Older diabetes patients are exposed to high risk of sarcopenia and physical disability. Thus, in order to prevent comorbidities coupled with expanding baby boomers globally, the adoption of diabetes drugs in geriatric population will rise in the future.
Insulin pump segment is forecasted to progress at over 11% CAGR during the forecast years. Robust growth is primarily attributed to preference for insulin pumps due to its advantages. It offers reduced episodes of severe glycemic conditions with less glucose variability. Also, ability of pumps to store information that can be further analysed and used in treatment planning will boost the segment revenue.
North America constituted 38.7% market share in 2019 and is expected witness robust growth rate in the forthcoming years. According to the American Diabetes Association, approximately 34.2 million Americans were living with diabetes in 2018. About 88 million people had prediabetes in the region.
U.S. antidiabetics market share will grow at 10.3% CAGR during the analysis period. increasing number in pediatric diabetes patients will drive the regional growth. Also, several established drug manufacturers have high penetration in the U.S. antidiabetics industry. Furthermore, increasing need for diabetes management among COVID-19 patients suffering from comorbidities will expand the market demand.
Antidiabetics Market Share
Some of the prominent business players operating in the antidiabetics industry share include:
These market players are adopting various inorganic growth strategies to increase market share and achieve competitive advantage.
Some of the recent industry developments:
The antidiabetics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026 for the following segments:
Click here to Buy Section of this Report
By Product
The above information is provided for the following regions and countries:
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →